Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/2022-503084-15-00
2022-503084-15-00RecruitingPhase 1

First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer

Deutsches Krebsforschungszentrum (DKFZ)4 sites in 1 country77 target enrollmentStarted: November 22, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
77
Locations
4
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 65+ years (65+ Years, 18-64 Years)
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Deutsches Krebsforschungszentrum (DKFZ)
Sponsor Class
Laboratory/Research/Testing facility
Responsible Party
Principal Investigator
Principal Investigator

KKE Translational Immunology, University Hospital Tuebingen

Scientific

Deutsches Krebsforschungszentrum (DKFZ)

Study Sites (4)

Loading locations...

Similar Trials

Not yet recruiting
Phase 1
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegaly
DRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95
Completed
Phase 1
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra peptide in healthy volunteers
2024-514225-30-00Universitaetsklinikum Heidelberg AöR45
Recruiting
Phase 1
A First-in-Human clinical trial assessing safety of ES2B-C001 with or without Montanide in patients with HER2 expressing metastatic breast cancer.
2024-516333-12-00Expres2ion Biotechnologies ApS27
Completed
Not Applicable
A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myelomasolide tumorentumor in the organs
NL-OMON44939Amgen42
Recruiting
Phase 1
A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma
2024-511843-24-00Emercell SAS10